Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Relacatib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Session 1 | EXPERIMENTAL | Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3. |
| Session 2 | EXPERIMENTAL | Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib. |
| Name | Type | Description |
|---|---|---|
| Relacatib | DRUG | Subjects will administer 60 or 120 mg tablets in Session 2 |
| Acetaminophen | DRUG | Acetaminophen will be administered orally |
| Ibuprofen | DRUG | Ibuprofen will be administered orally |
| Atorvastatin | DRUG | Atorvastatin will be administered orally |
Inclusion Criteria: * Healthy * Postmenopausal * Body weight \> 50 kg * Body mass index (BMI) between 19 and 30 * The subject is willing and able to give a signed and dated written informed consent prior to admission to the study * The subject is able to understand and comply with protocol requirem...
Relacatib is a small molecule being developed by GSK plc for osteoarthritis. It is currently in Phase 1 clinical development as an investigational therapy. The drug has been studied in a completed clinical trial involving patients with osteoarthritis.
Relacatib is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for the treatment of osteoarthritis.
Relacatib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial for the drug has been completed.
Relacatib has been studied in one completed Phase 1 clinical trial, identified as NCT00411190. This trial examined the effects of Relacatib on the metabolism of acetaminophen, ibuprofen, and atorvastatin in patients with osteoarthritis.
No, Relacatib is not the same as GSK. Relacatib is an investigational drug being developed by GSK plc, which is the company that makes the drug. GSK is the developer and manufacturer, while Relacatib is the drug candidate.